Basel: Roche has announced that the FDA has approved the VENTANA MET (SP44) RxDx Assay, the first companion diagnostic ...

Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has approved the perioperative regimen of ...

A study found that those who smoked for more than 30 years and 20 packs per day (a pack per day × 20 years) have a 54 times ...

Dr. Suresh Ramalingam discussed how the LAURA findings support the role of Tagrisso as a backbone therapy across multiple ...

A systematic review and subsequent expert review gave comprehensive insight into prognostic factors for patients receiving ...

The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment for certain people who have non-squamous non-small-cell lung cancer.

Almost a third of Americans are more than a year behind in cancer screening, more than half of them because of out-of-pocket ...

For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with ...

Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.

I never thought in a million years that this would happen to me … especially so young,” Brooklynite Jaclyn Keely told The ...

The agency granted accelerated approval based on a 35 percent response rate and more than 14 months of median overall survival in high expressers.

The antibody-drug conjugate is approved for previously treated advanced NSCLC patients with high c-Met protein overexpression ...